初诊多发性骨髓瘤治疗进展.pptVIP

初诊多发性骨髓瘤治疗进展;内容提要;治疗指征—有症状MM;治疗原则;指南推荐;;;;;;Bortezomib/Doxorubicin/Dexamethasone ;Bortezomib/Thalidomide/Dexamethasone ;Cyclophosphamide/Bortezomib/Dexamethasone ;Cyclophosphamide/Bortezomib/Dexamethasone ;;;Bortezomib;once-weekly schedule of bortezomib.;Lenalidomide/Dexamethasone ;Lenalidomide/Dexamethasone ;Lenalidomide/Dexamethasone ;Lenalidomide/Dexamethasone ;Lenalidomide/Dexamethasone ;Bortezomib/Lenalidomide/Dexamethasone ;Bortezomib/Lenalidomide/Dexamethasone ;其它方案;部分2期及3期临床试验结果;;;国外经验;UPFRONT 研究：VD vs VTD vs VMP;ORR:VD 73% VTD 80% VMP70% CR/nCR 率：VTD(40%)略高于 VMP(32%)/VD(30%) VTD (PN) 的毒性大于VMP PFS和OS：3组无差异; *;aComplete cytogenetics pro 762 pts (248 in continuous Rd, 261 in Rd18, and 253 in MPT); high-risk defined as t(4;14), t(14;16), or del(17p). CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; FIRST, Frontline Investigation of Revlimid and Dexamethasone versus Standard Thalidomide; ISS, International Staging System; MPT, melphalan, prednisone, thalidomide; pt, patient; Rd, lenalidomide plus low-dose dexamethasone; Rd18, lenalidomide plus low-dose dexamethasone for 18 cycles.;Patients (%);AMT, antimyeloma therapy; FIRST, Frontline Investigation of Revlimid and Dexamethasone versus Standard Thalidomide; MPT, melphalan, prednisone, thalidomide; Rd, lenalidomide plus low-dose dexamethasone; Rd18, lenalidomide plus low-dose dexamethasone for 18 cycles; TTP, time to progression. ;;FIRST研究：中位随访45.5个月，Rd持续和Rd18 vs MPT组 显示出显著的OS和PFS2优势;FIRST研究：中位随访37个月和45.5个月结果比较;*;;NDMM方案;NDMM方案;特殊患者NDMM方案; 谢 谢;谢谢观赏！